Diarrhea is a condition characterized by the frequent passage of loose or watery stools, often caused by infections, food intolerance, or underlying health issues. Globally, diarrhea alone accounts for approximately 0.5 million deaths among children under the age of five annually and stands as the second most common cause of mortality in this age group. The diarrhea drug pipeline is witnessing significant advancements, with improved therapies and innovative diarrhea therapeutics under development. The growing focus on enhancing treatment efficacy, addressing antimicrobial resistance, and improving supportive care is expected to drive substantial growth in the pipeline.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diarrhea.
Diarrhea is treated by maintaining hydration through oral rehydration solutions (ORS) to prevent dehydration. Medications like loperamide may reduce symptoms, while antibiotics are prescribed for bacterial infections. Dietary adjustments, such as consuming bland foods, also aid recovery. In severe cases, intravenous fluids may be required.
This product will be delivered within 3-5 business days.
Report Coverage
The Diarrhe Drug Pipeline Insight Report by the publisher gives comprehensive insights into diarrhea therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diarrhea. The diarrhea report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diarrhea pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diarrhea treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diarrhea.
Diarrhea Drug Pipeline Outlook
Diarrhea is a condition characterized by frequent, loose, or watery bowel movements. It occurs when the digestive system fails to absorb fluids properly or when excess fluids are secreted into the intestines. Causes include infections, food intolerance, medications, and digestive disorders. It can lead to dehydration if left untreated, especially in young children and older adults.Diarrhea is treated by maintaining hydration through oral rehydration solutions (ORS) to prevent dehydration. Medications like loperamide may reduce symptoms, while antibiotics are prescribed for bacterial infections. Dietary adjustments, such as consuming bland foods, also aid recovery. In severe cases, intravenous fluids may be required.
Diarrhea Epidemiology
Globally, diarrhea causes approximately 0.5 million deaths annually among children under five, making it the second leading cause of mortality in this group. Around 1.7 billion childhood diarrhea cases are recorded each year. In the United States, diarrheal illnesses account for 178.8 million cases annually, leading to 474,000 hospitalizations and 5,000 deaths. In Japan, chronic diarrhea affects approximately 3%-5% of the population, with higher prevalence among men, while India records 120,000 child deaths yearly.Diarrhea - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of diarrhea drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Biologics
- Probiotics
- Vaccines
- Peptides
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Diarrhea - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total diarrhea clinical trials.Diarrhea - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the diarrhea pipeline analysis include small molecules, biologics, probiotics, vaccines, peptides, and others. The diarrhea report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diarrhea.Diarrhea Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the diarrhea drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diarrhea therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diarrhea clinical trials:- GlaxoSmithKline
- Immuron Ltd.
- RedHill Biopharma Limited
- Lumen Bioscience, Inc.
- CinPhloro Pharma, LLC
- Tasly Pharmaceutical Group Co., Ltd.
- Chongqing Peg-Bio Biopharm Co., Ltd.
- AbbVie
- Lallemand Health Solutions
- Vedanta Biosciences, Inc.
- Crinetics Pharmaceuticals Inc.
- Pfizer
Diarrhea Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for diarrhea. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diarrhea drug candidates.Drug: Probiotic Formulation
A probiotic formulation is being investigated in a Phase IV clinical trial sponsored by Lallemand Health Solutions. The study aims to evaluate the safety and efficacy of a probiotic formulation in alleviating abdominal pain, abnormal defecation, anxiety, and depression and improving the quality of life in adults with irritable bowel syndrome with diarrhea (IBS-D). The trial is expected to be completed by November 2024Drug: Changkang Granules
Changkang Granules, sponsored by Tasly Pharmaceutical Group Co., Ltd, is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in treating irritable bowel syndrome with predominant diarrhea. This randomized, double-blind, placebo-controlled study aims to assess the therapeutic potential of Changkang Granules, a traditional Chinese medicine, with an estimated completion date of December 2026.Drug: Rifamycin SV-MMX
Rifamycin SV MMX, marketed as Aemcolo®, is a non-systemic, delayed-release antibiotic designed to target the lower intestine using Cosmo Pharmaceuticals' MMX® technology for controlled drug delivery. Rifamycin SV MMX is currently being evaluated in a Phase II clinical trial, conducted by RedHill Biopharma Limited, to assess its safety and efficacy in treating traveler's diarrhea in children aged 6 to 11 years. This double-blind study involves 142 participants receiving either Rifamycin SV MMX or a placebo with oral rehydration therapy (ORT).Reasons To Buy This Report
The Diarrhea Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for diarrhea. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diarrhea collaborations, regulatory environments, and potential growth opportunities.Key Questions Answered in the Diarrhea - Pipeline Insight Report
- Which companies/institutions are leading the diarrhea drug development?
- What is the efficacy and safety profile of diarrhea pipeline drugs?
- Which company is leading the diarrhea pipeline development activities?
- What is the current diarrhea commercial assessment?
- What are the opportunities and challenges present in the diarrhea drug pipeline landscape?
- What is the efficacy and safety profile of the diarrhea pipeline drugs?
- Which company is conducting major trials for diarrhea drugs?
- Which companies/institutions are involved in diarrhea collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in diarrhea?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Diarrhea
4 Patient Profile: Diarrhea
5 Diarrhea: Epidemiology Snapshot
6 Diarrhea: Market Dynamics
7 Diarrhea: Key Facts Covered
8 Diarrhea, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Diarrhea Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Diarrhea Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Diarrhea Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Diarrhea Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Diarrhea, Key Drug Pipeline Companies